Basdai Calculator (Bath Ankylosing Spondylitis Disease Activity Index)

What Is the BASDAI?

The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is a validated, patient-reported outcome measure designed to quantify disease activity in ankylosing spondylitis (AS) and related axial spondyloarthropathies. Developed at the Royal National Hospital for Rheumatic Diseases in Bath, UK, and published in 1994, the BASDAI captures six cardinal symptoms on a 0–10 numeric rating scale, producing a composite score that directly informs clinical decision-making and treatment escalation. The index has become a cornerstone of AS management globally, appearing in national and international treatment guidelines as a prerequisite for biologic therapy.

The BASDAI Formula Explained

The BASDAI is calculated using the following validated formula:

BASDAI = ( Q1 + Q2 + Q3 + Q4 + ( (Q5 + Q6) / 2 ) ) / 5

Questions 5 and 6 both assess morning stiffness — one measuring severity and one measuring duration — so their mean is computed before combining with the remaining four questions. Dividing the total by 5 normalises the composite to a continuous 0–10 scale, where higher values denote greater disease burden.

Variable Definitions

• Q1 – Fatigue / Tiredness (0–10): Overall level of fatigue or tiredness experienced over the past week. A score of 0 indicates no fatigue; 10 indicates very severe, debilitating fatigue.
• Q2 – Neck, Back or Hip Pain (0–10): Overall level of AS-related axial pain in the neck, back, or hips. Reflects the primary inflammatory pain domain of the disease.
• Q3 – Peripheral Joint Pain / Swelling (0–10): Pain or swelling in joints other than the spine, such as knees, ankles, or shoulders. Captures peripheral arthritis involvement.
• Q4 – Enthesitis / Localised Tenderness (0–10): Discomfort arising from areas tender to touch or pressure, reflecting enthesitis — inflammation at tendon and ligament insertion sites.
• Q5 – Morning Stiffness Severity (0–10): Severity of stiffness experienced from the time of waking. A score of 0 means no stiffness; 10 means very severe stiffness.
• Q6 – Morning Stiffness Duration (0–10): Duration of morning stiffness after waking, anchored at 0 = 0 hours, 5 = 1 hour, and 10 = 2 or more hours.

Step-by-Step Calculation

Follow these steps to compute a BASDAI score manually:

1. Record patient responses for Q1 through Q6 on a 0–10 scale.
2. Average the two morning stiffness questions: MS mean = (Q5 + Q6) / 2.
3. Sum the five components: Total = Q1 + Q2 + Q3 + Q4 + MS mean.
4. Divide by 5: BASDAI = Total / 5.

Worked Example

A 34-year-old patient with established AS reports: Q1 = 6, Q2 = 7, Q3 = 3, Q4 = 5, Q5 = 8, Q6 = 8. The morning stiffness mean equals (8 + 8) / 2 = 8. The total is 6 + 7 + 3 + 5 + 8 = 29. Dividing by 5 yields a BASDAI of 5.8 — moderate-to-high disease activity, exceeding the clinical action threshold of 4.0.

Interpreting BASDAI Scores

Scores fall on a continuous 0–10 scale. Clinicians apply the following widely recognised thresholds:

• 0.0 – 3.9: Inactive or low disease activity — monitoring without therapy escalation is appropriate.
• 4.0 – 6.9: Moderate disease activity — biologic therapy eligibility is typically met.
• 7.0 – 10.0: High or severe disease activity — prompt treatment review is warranted.

A BASDAI score of 4 or above is the internationally accepted threshold for active disease. According to the NCBI review of BASDAI and BASFI, a score ≥ 4 on two separate occasions at least four weeks apart forms a prerequisite for initiating biologic therapy — including TNF inhibitors and IL-17A inhibitors — across multiple national guidelines. Research published in PMC (2025) on refined BASDAI cut-off values further validates the 4.0 threshold while exploring optimised cut-points for specific clinical subgroups.

Clinical Applications

Rheumatologists use BASDAI to track disease course across sequential appointments, quantify treatment response to NSAIDs and biologics, and satisfy eligibility criteria required by payers and regulatory bodies. Serial BASDAI measurements — rather than isolated values — provide the most clinically actionable picture of disease trajectory. The index is also widely deployed in clinical trials as a primary or secondary endpoint, and its brevity (under two minutes to complete) supports routine use in busy outpatient settings.

Limitations

As a patient-reported tool, BASDAI reflects subjective symptom burden and may not correlate with objective inflammatory markers such as C-reactive protein (CRP) or MRI findings, particularly in patients with high pain sensitisation. Clinicians therefore frequently evaluate BASDAI alongside the Ankylosing Spondylitis Disease Activity Score (ASDAS), which integrates CRP into a composite measure, to obtain a more complete assessment of inflammatory disease activity.